TY - JOUR T1 - Multifactorial SARS-CoV-2 seroprofiling dissects interdependencies with human coronaviruses and predicts neutralization activity JF - medRxiv DO - 10.1101/2021.04.21.21255410 SP - 2021.04.21.21255410 AU - Irene A. Abela AU - Chloé Pasin AU - Magdalena Schwarzmüller AU - Selina Epp AU - Michèle E. Sickmann AU - Merle M. Schanz AU - Peter Rusert AU - Jacqueline Weber AU - Stefan Schmutz AU - Annette Audigé AU - Liridona Maliqi AU - Annika Hunziker AU - Maria C. Hesselman AU - Cyrille R. Niklaus AU - Jochen Gottschalk AU - Eméry Schindler AU - Alexander Wepf AU - Urs Karrer AU - Aline Wolfensberger AU - Silvana K. Rampini AU - Patrick M. Meyer Sauteur AU - Christoph Berger AU - Michael Huber AU - Jürg Böni AU - Dominique L. Braun AU - Maddalena Marconato AU - Markus G. Manz AU - Beat M. Frey AU - Huldrych F. Günthard AU - Roger D. Kouyos AU - Alexandra Trkola Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/21/2021.04.21.21255410.abstract N2 - Definition of SARS-CoV-2 antibody responses is essential to verify protective immunity following infection and vaccination. Here, we devised a versatile serological test, named ABCORA, that is based on a multifactorial analysis of SARS-CoV-2 and circulating human coronavirus (HCoV) antibody responses. Utilizing empirical tailored cut-offs and computational approaches based on training and validation cohorts comprising pre-pandemic (N=825) and SARS-CoV-2 infected plasma donors (N=389), we defined several analysis strategies that allow a highly accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity. Intriguingly, HCoV reactivity was significantly higher in SARS-CoV-2 negative donors. Amongst SARS-CoV-2 infected individuals, elevated SARS-CoV-2 responses were linked to higher HCoV activity suggesting that pre-existing HCoV immunity may confer protection against SARS-CoV-2 acquisition and promote development of SARS-CoV-2 specific antibody responses. Deciphering interdependencies between SARS-CoV-2 and HCoV immunity should be enforced as understanding their impact on infection may allow soliciting cross-protective activities for broader coronavirus prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant of the Pandemiefonds of the University of Zurich Foundation to A.T., a grant of the Swiss Red Cross to B.F. and A.T., a grant of the University Hospital Zurich Innovation Grant to M.G.M., the Swiss National Science Foundation grant 31CA30_196906 to H.F.G., A.T., R.K. and the Gilead COVID-19 RFP Research Program COMMIT Grant #: IN-SW-983-6078 (to H.F.G., A.T., R.K.). I.A.A. is supported by a research grant of the Promedica Foundation. Roche Diagnostics supported the study with providing test material for a proportion of the Elecsys S tests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum and plasma samples collected pre and post emergence of SARS-CoV-2 in Switzerland (pre and post February 2020, respectively) were included. No patient enrollment was conducted for the present study. All experiments involving samples from human donors were conducted with the approval of the responsible local ethics committee Zurich, Switzerland (BASEC Nrs 2020-01327, 2020-00363; Req-397 2021-00437; 2020-00787), in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation. Samples were obtained from the following sources: i) Zurich blood donation services (ZHBDS): Anonymized healthy adult plasma from pre-pandemic time points (January 2019, May 2019 and January 2020) and from the first wave of the pandemic in Zurich, Switzerland (May 2020) were provided by the ZHBDS internal serum repository (BASEC 2020-00363). ii) Anonymized leftover specimens from routine diagnostics at the Institute of Medical Virology, University of Zurich, the University Children Hospital Zurich and the Cantonal Hospital Winterthur (BASEC Nrs 2020-01327, Req-2021-00437). iii) Healthcare workers with RT-PCR confirmed SARS-CoV-2 infection participating in a study at the University Hospital Zurich (BASEC 2020-00363). iv) Male plasma donors participating in a SARS-CoV-2 plasma therapy study conducted at the University Hospital Zurich (CPT-ZHP, Swissmedic 2020TpP1004; BASEC 2020-00787). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available in the peer-reviewed journal version. ER -